Printed From:

IMPROVE GLYCEMIC CONTROL WITH TOUJEO®

Toujeo®: significant A1C reductions and demonstrated safety in patients previously not at goal1-5

Choose a study below to learn more.

T2DM, insulin-naive

Hypothetical patient profile; individual results may vary.

Helen is an insulin-naive patient with T2DM who has resisted initiating basal insulin for years.

Consider Toujeo® for appropriate patients like Helen.

Baseline A1C: 8.2%; FPG: 180 mg/dL

Powerful A1C reduction1,2
-1.42% Toujeo® n=432
-1.46% Lantus® n=430

Data reflect results 6 months after initiating Toujeo®.

  • Toujeo® met the primary study endpoint of A1C reduction [prespecified noninferiority margin of 0.4% and the 95% CI]1-5
  • Patients on Toujeo® were titrated to a higher average dose (11%-17.5%) than those on Lantus®1
  • After changing to Toujeo®, patients may experience a temporary rise in FPG in the first weeks of therapy1
Proven safety1,2
Low incidence of severe hypoglycemiaa 0.9%
Documented
symptomatic
hypoglycemiab
8%
Weight gain +1.1lb
  • Most common adverse events (with incidence ≥5%) with Toujeo® in patients with T2DM and T1DM were nasopharyngitis (7.1% and 12.8%, respectively) and upper respiratory infection (5.7% and 9.5%, respectively)1
  • There were no clinically important differences in body weight between treatment groups1
  • Incidence of severe hypoglycemia when part of a multiple-dose injection regimen: 6.6% in T1DM, 5% in T2DM; when part of a basal insulin-only regimen: 1.0% and 0.9% in two T2DM studies1
  • Hypoglycemia can be life-threatening. It is important to educate your patients accordingly
  • To minimize the risk of hypoglycemia, titrate the dose of Toujeo® no more frequently than every 3 to 4 days1
T2DM, switched from another basal

Hypothetical patient profile; individual results may vary.

Sally is a patient with T2DM. Her FPG values are not consistently within range with her current basal insulin.

Consider Toujeo® for appropriate patients like Sally.

Baseline A1C: 8.2%; FPG: 149 mg/dL

Powerful A1C reduction1,3
-0.73% Toujeo® n=403
-0.70% Lantus® n=405

Data reflect results 6 months after initiating Toujeo®.

  • Toujeo® met the primary study endpoint of A1C reduction [prespecified noninferiority margin of 0.4% and the 95% CI]1-5
  • Patients on Toujeo® were titrated to a higher average dose (11%-17.5%) than those on Lantus®1
  • After changing to Toujeo®, patients may experience a temporary rise in FPG in the first weeks of therapy1
Proven safety1,3
Low incidence of severe hypoglycemiaa 1.0%
Documented
symptomatic
hypoglycemiab
20.6%
Weight gain +0.2lb
  • Most common adverse events (with incidence ≥5%) with Toujeo® in patients with T2DM and T1DM were nasopharyngitis (7.1% and 12.8%, respectively) and upper respiratory infection (5.7% and 9.5%, respectively)1
  • There were no clinically important differences in body weight between treatment groups1
  • Incidence of severe hypoglycemia when part of a multiple-dose injection regimen: 6.6% in T1DM, 5% in T2DM; when part of a basal insulin-only regimen: 1.0% and 0.9% in two T2DM studies1
  • Hypoglycemia can be life-threatening. It is important to educate your patients accordingly
  • To minimize the risk of hypoglycemia, titrate the dose of Toujeo® no more frequently than every 3 to 4 days1
T2DM, switched from another basal + bolus regimen

Hypothetical patient profile; individual results may vary.

Richard is a patient with T2DM. His morning BG levels are elevated on his current therapy. He wants to achieve stable BG levels.

Consider Toujeo® for appropriate patients like Richard.

Baseline A1C: 8.6%; FPG: 157 mg/dL

Significant A1C reduction1,4
-0.9% Toujeo® n=404
-0.87% Lantus® n=400

Data reflect results 6 months after initiating Toujeo®.

  • Toujeo® met the primary study endpoint of A1C reduction [prespecified noninferiority margin of 0.4% and the 95% CI]1-5
  • Patients on Toujeo® were titrated to a higher average dose (11%-17.5%) than those on Lantus®1
  • After changing to Toujeo®, patients may experience a temporary rise in FPG in the first weeks of therapy1
Proven safety1,4
Severe hypoglycemiaa 5%
Documented
symptomatic
hypoglycemiab
37%
Weight gain +2lb
  • Most common adverse events (with incidence ≥5%) with Toujeo® in patients with T2DM and T1DM were nasopharyngitis (7.1% and 12.8%, respectively) and upper respiratory infection (5.7% and 9.5%, respectively)1
  • There were no clinically important differences in body weight between treatment groups1
T1DM

Hypothetical patient profile; individual results may vary.

Eva is a patient with T1DM. She’s physically active and committed to reaching the BG goals recommended by her physician.

Consider Toujeo® for appropriate patients like Eva.

Baseline A1C: 7.4%; FPG: 156 mg/dL

Significant A1C reduction1,5
-0.40% Toujeo® n=274
-0.44% Lantus® n=275

Data reflect results 6 months after initiating Toujeo®.

  • Toujeo® met the primary study endpoint of A1C reduction [prespecified noninferiority margin of 0.4% and the 95% CI]1-5
  • Patients on Toujeo® were titrated to a higher average dose (11%-17.5%) than those on Lantus®1
  • After changing to Toujeo®, patients may experience a temporary rise in FPG in the first weeks of therapy1
Proven safety1,5
Severe hypoglycemiaa 6.6%
Documented
symptomatic
hypoglycemiab
69.0%
Weight gain +1lb
  • Most common adverse events (with incidence ≥5%) with Toujeo® in patients with T2DM and T1DM were nasopharyngitis (7.1% and 12.8%, respectively) and upper respiratory infection (5.7% and 9.5%, respectively)1
  • There were no clinically important differences in body weight between treatment groups1

BG, blood glucose; FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

a Severe hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.

b Documented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.